FluoGuide A/S AI Stock Analysis
Want to see SE:FLUO full AI Analyst Report?
FluoGuide A/S (FLUO) AI Stock Analysis
FluoGuide A/S
(Nasdaq OMX AB:FLUO)
FluoGuide scores near the low end of the range, driven primarily by weak financials: essentially zero revenue, a widening 46.2 million net loss, and 44.3 million of annual cash burn against only 30.7 million of remaining equity. Leverage rose from near zero to roughly 0.9 times equity in a single year, adding refinancing and dilution risk to an already tight runway. Technicals reinforce the caution, with the price below all major moving averages and negative MACD momentum. Valuation provides no cushion — earnings are negative and no dividend is paid. The investment case rests entirely on clinical pipeline progress and the ability to raise capital, not on current financial performance.
FluoGuide A/S (FLUO) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 459.42M
- Dividend Yield
- ―
- Average Volume (3M)
- 5,056
- Price to Earnings (P/E)
- -7.1
- Beta (1Y)
- 0.11
- Revenue Growth
- ―
- EPS Growth
- -23.57%
- Country
- Sweden
- Employees
- 7
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
FluoGuide A/S Business Overview & Revenue Model
Company Description
FluoGuide A/S is a Danish life science company dedicated to developing and commercializing advanced surgical solutions. Its flagship investigational compound, FG001, is currently undergoing Phase I/II clinical trials for the treatment of high-grade g...
How the Company Makes Money
FluoGuide’s business model is centered on developing proprietary fluorescence imaging agents and monetizing them through (1) future commercial sales (if/when regulatory approvals are obtained) and/or (2) partnering and licensing transactions with lar...
FluoGuide A/S Financial Statement Overview
Summary
All three financial verticals score poorly. Revenue has effectively vanished (just 54 thousand in the TTM period), while the net loss widened to 46.2 million and operating loss to 48.5 million. Cash burn is the sharpest concern: free cash flow of -44.3 million has worsened for three straight years and now exceeds the entire 30.7 million equity base. The balance sheet is the relative bright spot but is deteriorating — equity fell from 54.6 million to 30.7 million and debt jumped from near zero to 27.6 million, lifting debt-to-equity to roughly 0.90. The company is fully dependent on external funding, with likely dilution or refinancing within about a year. Spending is directed at pipeline development rather than covering commercial shortfalls, and capital expenditure is negligible, which provides modest offset.
Income Statement
9Very NegativeBalance Sheet
33NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 54.00K | 0 | 385.00K | 423.00K | 6.51M | 9.61M |
| Gross Profit | -416.92K | -571.17K | 385.00K | 423.00K | 6.51M | 9.61M |
| EBITDA | -48.08M | -40.42M | -32.58M | -43.66M | -32.21M | -28.65M |
| Net Income | -46.24M | -40.39M | -28.96M | -38.38M | -27.34M | -23.77M |
Balance Sheet | ||||||
| Total Assets | 65.25M | 88.34M | 28.38M | 29.61M | 35.62M | 53.31M |
| Cash, Cash Equivalents and Short-Term Investments | 49.92M | 78.84M | 18.61M | 21.67M | 26.01M | 46.76M |
| Total Debt | 27.56M | 28.30M | 624.00K | 10.83M | 205.00K | 57.00K |
| Total Liabilities | 34.51M | 33.78M | 5.31M | 16.89M | 3.65M | 14.61M |
| Stockholders Equity | 30.74M | 54.56M | 23.07M | 12.72M | 31.97M | 38.70M |
Cash Flow | ||||||
| Free Cash Flow | -44.28M | -37.83M | -30.00M | -31.81M | -37.71M | -15.06M |
| Operating Cash Flow | -43.80M | -37.83M | -29.15M | -31.81M | -37.65M | -15.06M |
| Investing Cash Flow | -30.37M | -30.61M | -987.00K | -37.00K | -117.00K | 0 |
| Financing Cash Flow | 74.76M | 99.33M | 27.08M | 27.50M | 17.02M | 51.18M |
FluoGuide A/S Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:FLUO, the sentiment is Negative. The current price of 31.60 is above the 20-day moving average (MA) of 30.14, below the 50-day MA of 32.03, and below the 200-day MA of 36.18, indicating a bearish trend. The MACD of -0.84 indicates Positive momentum. The RSI at 36.13 is Neutral, neither overbought nor oversold. The STOCH value of 23.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:FLUO.
FluoGuide A/S Peers Comparison
Overall Rating
SE:FLUI65Neutral
SE:BINV49Neutral
SE:ONCO44Neutral
SE:SPAGO42Neutral
SE:BIOVIC.B41Neutral
SE:FLUO40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 65Neutral | SEK 32.83M | 6.37 | 34.47% | ― | 630.57% | ― | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 49Neutral | SEK 172.08M | -0.35 | -128.54% | ― | -83.67% | -50.29% | |
| 44Neutral | SEK 747.11M | -2.67 | ― | ― | 65.37% | 43.28% | |
| 42Neutral | SEK 35.13M | -1.05 | -87.37% | ― | -97.52% | 31.31% | |
| 41Neutral | SEK 86.35M | -1.21 | -75.51% | ― | 56.06% | 63.95% | |
| 40Underperform | SEK 516.64M | -7.06 | ― | ― | ― | -23.57% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:FLUO | FluoGuide A/S | 31.60 | -8.10 | -20.40% | |
| SE:BINV | BioInvent International AB | 2.62 | -28.28 | -91.54% | |
| SE:ONCO | Oncopeptides AB | 1.68 | -3.29 | -66.19% | |
| SE:BIOVIC.B | Biovica International AB Class B | 0.30 | -0.23 | -43.82% | |
| SE:SPAGO | Spago Nanomedical AB | 0.04 | -0.06 | -59.00% | |
| SE:FLUI | Fluicell AB | 23.00 | 11.40 | 98.28% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 27, 2026
